# Evaluation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ELA026 in Single and Multiple Doses in Healthy Volunteers

> **NCT05556863** · PHASE1 · COMPLETED · sponsor: **Electra Therapeutics Inc.** · enrollment: 91 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** ELA026
- **DRUG:** ELA026

## Key facts

- **NCT ID:** NCT05556863
- **Lead sponsor:** Electra Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-18
- **Primary completion:** 2023-11-20
- **Final completion:** 2023-11-20
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2024-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05556863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05556863, "Evaluation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ELA026 in Single and Multiple Doses in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05556863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*